917383-03-0

Basic information

• Product Name: Cyclohexanecarboxamide, 4,4-difluoro-N-methoxy-N-methyl-
• CAS NO: 917383-03-0
• Molecular Formula: C9H15F2NO2
• Molecular Weight: 207.22
• Mol File: 917383-03-0.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarboxamide, 4,4-difluoro-N-methoxy-N-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxamide, 4,4-difluoro-N-methoxy-N-methyl-(917383-03-0)
• EPA Substance Registry System: Cyclohexanecarboxamide, 4,4-difluoro-N-methoxy-N-methyl-(917383-03-0)

Safety Data

• Hazardous Substances Data: 917383-03-0(Hazardous Substances Data)

Upstream product

• 178312-47-5 ethyl 4,4-difluorocyclohexane-1-carboxylate 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 122665-97-8 4,4-difluorocyclohexanecarboxylic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 

Downstream Products

• 265108-36-9 4,4-difluorocyclohexane carboxyaldehyde 
• 22419-35-8 4,4-difluorocyclohexanol 
• 1332633-13-2 2-(4,4-difluoro-cyclohexyloxy)-4-fluoro-1-nitro-benzene 
• 1450660-63-5 (±)-1-(4,4-difluorocyclohexyl)ethanamine 

Relevant articles and documents

Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors

Inhibition of transforming growth factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50 values of 44 and 42.5 nM, respectively. Compound 15r also displayed better oral plasma exposure and excellent bioavailability than LY-3200882, and in vivo inhibited 65.7% of the tumor growth in a CT26 xenograft mouse model.

TRICYCLIC COMPOUND SERVING AS IMMUNOMODULATOR

Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.